WHO Cautions Against Assuming Ebola Vaccine Protects Against Bundibugyo Virus

WHO Cautions Against Assuming Ebola Vaccine Protects Against Bundibugyo Virus The World Health Organization WHO has cautioned against assuming that Ervebo, the only licensed Ebola vaccine, can protect people against the Bundibugyo virus amid an ongoing outbreak. The warning highlights uncertainty over whether the vaccine, which was developed and licensed for protection against Zaire ebolavirus, provides protection against the Bundibugyo species responsible for the current outbreak. According to the WHO, there is currently insufficient evidence to conclude that Ervebo can prevent infection with Bundibugyo virus. Health authorities and medical teams are therefore being urged to avoid treating vaccination with Ervebo as guaranteed protection against the virus. The development presents an additional challenge for outbreak response efforts, particularly as health officials work to contain transmission and protect frontline workers and communities at risk. Scientists and public health authorities continue to monitor the outbreak and assess available measures for preventing and controlling the spread of the virus. Ebola viruses can cause severe illness and outbreaks require rapid identification of cases, isolation, contact tracing, infection prevention measures and other public health interventions. The WHO’s caution underscores the importance of relying on evidence-based measures while research continues into the effectiveness of existing vaccines against different Ebola virus species.